Clinigen Group Plc (CLIN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Clinigen Group Plc (CLIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013154
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:83
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Clinigen Group plc (Clinigen Group) is a pharmaceutical and services company that provides access to medicines, clinical trials, unlicensed and commercial supply. The company acquires and licenses essential commercial medicines including cardioxane, ethyol, foscavir, savene and vibativ. It offers clinical trial services, IDIS managed access, global access and strategic services. Clinigen Group’s clinical trial services comprise direct-to-site delivery, demand-driven labelling and distribution, ancillary supply, investigator-initiated trial services, and technical consultancy services. It serves pharmaceutical and biotechnology companies; and healthcare professionals. The company has operations in New Zealand, Australia, Japan, the US, Singapore, South Africa and the UK . Clinigen Group is headquartered in Burton-on-Trent, the UK.

Clinigen Group Plc (CLIN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Clinigen Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Clinigen Group Plc, Medical Devices Deals, 2011 to YTD 2017 11
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Clinigen Acquires Rights to Totect from Biocodex USA 14
Clinigen Group Acquires Ethyol from AstraZeneca 15
Clinigen Acquires Savene, Oncology Support Therapy, From SpePharm 16
Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For US$33 Million 17
Partnerships 18
Clinigen Enters into Agreement with Shionogi 18
Clinigen Enters into Distribution Agreement with Romark Labs 19
Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 20
Clinigen Group Enters into Distribution Agreement with BioQ Pharma 21
Clinigen Group Partners with Horizon Pharma 22
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 23
Cumberland Pharma Enters into Agreement with Clinigen 24
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 25
Link Healthcare Enters Into Agreement With Sanochemia Pharmazeutika For Secrelux 26
EirGen Pharma Enters into Agreement with Equity Pharma 27
Licensing Agreements 28
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 28
Clinigen Extends Licensing Agreement with Hospira for Foscavir 29
Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 30
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 32
NobelPharma Enters Into Licensing Agreement With Clinigen For Foscavir 33
Clinigen Enters Into Licensing Agreement With Hospira For Foscavir 34
Link Healthcare Enters into Licensing Agreement with Salix Pharma for Relistor 35
Equity Offering 36
Clinigen Completes IPO For US$16 Million 36
Acquisition 38
Clinigen to Acquire Quantum Pharma for USD199 Million 38
Clinigen Group Acquires Link Healthcare for USD155.2 Million 39
Clinigen Group Acquires Idis Group for USD338 Million 41
Link Healthcare Acquires Equity Pharma Holdings, Pharma And Medical Technology Company 43
Clinigen Group Plc – Key Competitors 44
Clinigen Group Plc – Key Employees 45
Clinigen Group Plc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 48
Financial Announcements 48
Sep 28, 2017: Clinigen Group: Full Year Results for the Year Ended 30 June 2017 48
Mar 15, 2017: Clinigen Group: Strong H1 Performance with Adjusted EPS up 31% 49
Jan 25, 2017: Clinigen Group HY trading update: strong H1 performance with gross profit up 34% 56
Sep 28, 2016: Clinigen Group: Transformational Year Delivers 25% Growth In Adjusted EPS 58
Jul 20, 2016: Strong second half performance completes transformational year for Clinigen 67
Mar 02, 2016: Clinigen Group Announces Continued Strong Growth With Eps Up 21% 69
Mar 02, 2016: Continued Strong Growth With EPS Up 21% 75
Jan 19, 2016: Clinigen Group announces Half year trading update-2016 76
Corporate Communications 77
Nov 01, 2017: Clinigen Group: Board changes 77
Sep 28, 2016: Shaun Chilton to take over as Chief Executive Officer 79
Other Significant Developments 80
Jul 18, 2017: Clinigen Group: Year End Trading Update 80
Mar 30, 2016: Clinigen Group has become a full member of the European Alliance for Access to Safe Medicines and Alliance for Safe Online Pharmacy in the EU 82
Appendix 83
Methodology 83
About GlobalData 83
Contact Us 83
Disclaimer 83

List of Tables
Clinigen Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Clinigen Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Clinigen Group Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Clinigen Group Plc, Medical Devices Deals, 2011 to YTD 2017 11
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Clinigen Acquires Rights to Totect from Biocodex USA 14
Clinigen Group Acquires Ethyol from AstraZeneca 15
Clinigen Acquires Savene, Oncology Support Therapy, From SpePharm 16
Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For US$33 Million 17
Clinigen Enters into Agreement with Shionogi 18
Clinigen Enters into Distribution Agreement with Romark Labs 19
Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 20
Clinigen Group Enters into Distribution Agreement with BioQ Pharma 21
Clinigen Group Partners with Horizon Pharma 22
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 23
Cumberland Pharma Enters into Agreement with Clinigen 24
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 25
Link Healthcare Enters Into Agreement With Sanochemia Pharmazeutika For Secrelux 26
EirGen Pharma Enters into Agreement with Equity Pharma 27
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 28
Clinigen Extends Licensing Agreement with Hospira for Foscavir 29
Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 30
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 32
NobelPharma Enters Into Licensing Agreement With Clinigen For Foscavir 33
Clinigen Enters Into Licensing Agreement With Hospira For Foscavir 34
Link Healthcare Enters into Licensing Agreement with Salix Pharma for Relistor 35
Clinigen Completes IPO For US$16 Million 36
Clinigen to Acquire Quantum Pharma for USD199 Million 38
Clinigen Group Acquires Link Healthcare for USD155.2 Million 39
Clinigen Group Acquires Idis Group for USD338 Million 41
Link Healthcare Acquires Equity Pharma Holdings, Pharma And Medical Technology Company 43
Clinigen Group Plc, Key Competitors 44
Clinigen Group Plc, Key Employees 45
Clinigen Group Plc, Subsidiaries 46

★海外企業調査レポート[Clinigen Group Plc (CLIN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Juroku Bank Ltd:企業の戦略・SWOT・財務情報
    The Juroku Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Juroku Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Fives:企業の戦略・SWOT・財務情報
    Fives - Strategy, SWOT and Corporate Finance Report Summary Fives - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • Gartner Inc (IT):企業の財務・戦略的SWOT分析
    Gartner Inc (IT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cooperativa Muratori & Cementisti C.M.C di Ravenna:企業の戦略・SWOT・財務分析
    Cooperativa Muratori & Cementisti C.M.C di Ravenna - Strategy, SWOT and Corporate Finance Report Summary Cooperativa Muratori & Cementisti C.M.C di Ravenna - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …
  • Vigo Coal Company Incorporated:企業の戦略・SWOT・財務情報
    Vigo Coal Company Incorporated - Strategy, SWOT and Corporate Finance Report Summary Vigo Coal Company Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Galadari Hotels (Lanka) PLC :企業の戦略・SWOT・財務情報
    Galadari Hotels (Lanka) PLC - Strategy, SWOT and Corporate Finance Report Summary Galadari Hotels (Lanka) PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Aesica Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Aesica Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Solstad Farstad ASA (SOFF):石油・ガス:M&Aディール及び事業提携情報
    Summary Solstad Farstad ASA (Solstad), formerly Solstad Offshore ASA is an oil and gas company that provides vessel operation solutions. The company offers carbon footprint, climate neutral network, offshore shipping, green operations, and rainforest protection, documentation programs, and others. I …
  • Gulfsands Petroleum plc (GPX):企業の財務・戦略的SWOT分析
    Summary Gulfsands Petroleum plc (Gulfsands) is an oil and gas company that offers exploration, development, and production services. The company carries out acquisition, exploration, develops, and produces oil and natural gas. It holds interests in oil exploration and development projects in the Syr …
  • Gulf Island Fabrication Inc (GIFI):企業の財務・戦略的SWOT分析
    Gulf Island Fabrication Inc (GIFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • The Wistar Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary The Wistar Institute (Wistar) is a biomedical research institute that carries out medical research and training. The institute performs research in the areas of cancer, infectious diseases, immunology and vaccine development. It also conducts research on genes, gene expression, and DNA biolo …
  • Do & Co Poland Sp.Z.O.O
    Do & Co Poland Sp.Z.O.O - Strategy, SWOT and Corporate Finance Report Summary Do & Co Poland Sp.Z.O.O - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nightingale Informatix Corp (NGH)-医療機器分野:企業M&A・提携分析
    Summary Nightingale Informatix Corp (Nightingale) is a healthcare technology company that develops, markets and licenses application software and related services. The company offers practice management, billing solutions, medical records and interoperability products. It provides web based document …
  • PTC Therapeutics Inc (PTCT)-製薬・医療分野:企業M&A・提携分析
    Summary PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and commercializes orally active small molecule therapeutics that target post transcriptional control. The company's pipeline products include an orally administered small-molecule targeted at genetic disorders due to a nonsense mu …
  • Huge China Holdings Limited (428):企業の財務・戦略的SWOT分析
    Huge China Holdings Limited (428) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Cellestia Biotech AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Cellestia Biotech AG (Cellestia Biotech) is a biopharmaceutical company that develops anti-cancer drugs for the treatment of oncology and immunological disorders. The company's lead compound includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymp …
  • Concord New Energy Group Ltd (182):企業の財務・戦略的SWOT分析
    Concord New Energy Group Ltd (182) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Hogan Lovells International LLP:企業の戦略的SWOT分析
    Hogan Lovells International LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Jo-Ann Stores, Inc.:戦略・SWOT・企業財務分析
    Jo-Ann Stores, Inc. - Strategy, SWOT and Corporate Finance Report Summary Jo-Ann Stores, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Stryker Corp (SYK):医療機器:M&Aディール及び事業提携情報
    Summary Stryker Corp (Stryker) is a medical technology company that manufactures an array of orthopaedic, medical and surgical, and neurotechnology and spine products and allied services. Its major products include orthopaedic implants; surgical equipment and surgical navigation systems; patient han …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆